Effect of olmesartan on pharmacodynamics and pharmacokinetics of glimepiride and metformin combination in animal models
Abstract
To establish the safety and efficacy of drug-drug combinations in diabetic hypertensive patients, the present study was designed to identify the pharmacodynamic and pharmacokinetic influence of olmesartan on glimepiride + metformin combination in normal rats, diabetic rats and normal rabbits using treatment of single and multiple doses. Blood samples were analyzed for blood glucose by GOD/POD method, insulin by elISA and serum glimepiride levels by HPlC method at pre-determined time intervals. Olmesartan showed significant synergistic hypoglycemic activity with glimepiride + metformin as well as elevated serum insulin levels in single and multiple-dose combinations in both rats and rabbits. The pharmacokinetic interactions of this combination are evidenced by a significant increase in AUMC0-t, AUMC0-∞ and MRT and there is a decrease in clearance (Cl) of glimepiride + metformin with single and multiple-dose treatment of olmesartan. Hence, care must be taken by physicians while prescribing olmesartan and glimepiride + metformin combination in a clinical situation.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.